The global market for shotgun metagenomics clinical reporting is poised for significant growth, driven by the increasing adoption of advanced genomic testing for diagnosing infectious diseases. According to a recent report added to ResearchAndMarkets.com, the market is expected to expand from $1.58 billion in 2025 to $1.83 billion in 2026, reflecting a compound annual growth rate (CAGR) of 16.4%.
This growth trajectory is supported by advancements in next-generation sequencing technologies, a surge in demand for diagnostics during infectious disease outbreaks, and enhanced funding for microbiology and clinical genomics research. The expansion of molecular testing infrastructure in hospital laboratories and heightened awareness of the need to monitor antimicrobial resistance are also contributing to the increased adoption of shotgun metagenomics clinical reporting.
By 2030, the market is projected to reach $3.4 billion, growing at a CAGR of 16.7%. Key factors driving this growth include the broader adoption of precision medicine and personalized diagnostics, the increasing use of artificial intelligence in genomic data interpretation, and the development of decentralized and point-of-care sequencing systems. There is also a rising demand for rapid pathogen detection in critical care settings and for cloud-based bioinformatics platforms that facilitate efficient clinical workflows.
Several trends are shaping the shotgun metagenomics clinical reporting market, including AI-powered pathogen detection, automated clinical interpretation, cloud-based genomic data sharing, and ultra-rapid sequencing for point-of-care infectious disease testing. Integrated genomic analytics for predicting antimicrobial resistance and decentralized sequencing systems for hospital-based metagenomic testing are anticipated to influence market development through 2030.
The prevalence of infectious diseases is a significant factor propelling market growth. Increased global connectivity and population movement have led to more frequent disease outbreaks, thus creating a demand for faster and more comprehensive diagnostic methods. Shotgun metagenomics clinical reporting can identify pathogens, antimicrobial resistance markers, and co-infections directly from clinical samples, aiding healthcare providers in making accurate diagnoses and selecting targeted treatments.
According to the World Health Organization, approximately 8.2 million people were newly diagnosed with tuberculosis in 2023, compared to 7.5 million in 2022, marking an increase of about 9.3%. This underscores the ongoing burden of infectious diseases and the necessity for advanced clinical diagnostic technologies that support timely treatment decisions.
Innovation in the market is increasingly focused on respiratory genomic testing and the analysis of microbial cell-free DNA from clinical fluids. In April 2025, Karius Inc. launched Karius Focus BAL, a metagenomic sequencing test that analyzes bronchoalveolar lavage fluid. This test is designed to identify over 500 pathogens and deliver diagnostic results within one day of sample receipt. It also detected 50% more causes of infectious pneumonia than conventional testing methods, highlighting the potential value of advanced metagenomic diagnostics for vulnerable patient populations.
Strategic partnerships are also expanding access to infectious disease testing. In April 2026, Karius Inc. partnered with Mayo Clinic Laboratories to offer the Karius Spectrum and Karius Focus | BAL tests through Mayo Clinic Laboratories. This collaboration aims to improve access to comprehensive pathogen detection and clinical reporting while supporting the broader adoption of advanced metagenomic testing.
North America led the shotgun metagenomics clinical reporting market in 2025, benefiting from established healthcare infrastructure, genomic research capabilities, and the early adoption of advanced molecular diagnostics. The Asia-Pacific region is expected to be the fastest-growing during the forecast period. The market analysis covers regions including Asia-Pacific, Southeast Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. Countries analyzed include Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, the United Kingdom, the United States, Canada, Italy, and Spain.
Footnotes:
- The global shotgun metagenomics clinical reporting market is projected to grow from $1.58 billion in 2025 to $1.83 billion in 2026. Source.
- The market is forecast to reach $3.4 billion by 2030, expanding at a CAGR of 16.7%. Source.
- Approximately 8.2 million people were newly diagnosed with tuberculosis in 2023. Source.
- In April 2025, Karius Inc. launched Karius Focus BAL, a metagenomic sequencing test. Source.
Featured Image: Megapixl @ Marilyna
